CRISPR Therapeutics (CRSP) Stock Price, Quote, News & History | Benzinga

CRISPR Therapeutics AG (CRSP) Stock Price, Quote, News & History

CRSPNASDAQ

Trade with Public

Trade with Public

$59.50

1.382.37%

At close: Aug 20, 5:00 PM EST

$59.30

1.182.03%

Pre-Market: 5:17 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$59.50

Volume / Avg.

2.63K / 1.68M

Day Range

- - -

52 Wk Range

44.12 - 78.48

Market Cap

$5.73B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

22.28%

Days to Cover

11.52

Recent CRISPR Therapeutics AG News

Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.

Mohd Haider

Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.

Mohd Haider

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.

Avi Kapoor

Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in today's session.

Avi Kapoor

Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far

Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the technology-heavy Nasdaq 100 Index.

Crispus Nyaga

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-369.58M

Investing Cash Flow (TTM)

-548.43M

Financing Cash Flow (TTM)

1.01B

Free Cash Flow (TTM)

-373.80M

Capital Expenditure (TTM)

-4.22M

Net Change in Cash (TTM)

94.26M

Analyst Trends and Forecast

1

Mar

1

1

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.17B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

512.85

PB Ratio (TTM)

3.29

Earnings Yield % (TTM)

-7.92%

Earnings Yield % (FWD)

-8.11%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$18.06

Company Debt

Total Debt

$586.20M

LT Debt

$586.20M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$291.34M

Debt to Equity

0.45

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$59.50

Volume / Avg.

2.63K / 1.68M

Day Range

- - -

52 Wk Range

44.12 - 78.48

Market Cap

$5.73B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

22.28%

Days to Cover

11.52

About

Sector

Health Care

Industry

Biotechnology

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revol...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy CRISPR Therapeutics (CRSP) stock?

A

You can purchase shares of CRISPR Therapeutics (NASDAQ:CRSP) through any online brokerage.

View our list of the best stock brokerages

Q

Who are CRISPR Therapeutics (CRSP) competitors?

A

Other companies in CRISPR Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for CRISPR Therapeutics (CRSP) stock?

A

CRISPR Therapeutics has a consensus price target of $72.23.

Q

What is the current price for CRISPR Therapeutics (CRSP)?

A

The stock price for CRISPR Therapeutics (NASDAQ: CRSP) is $59.3 last updated August 24, 2026 at 5:17 AM EDT.

Q

Does CRISPR Therapeutics (CRSP) pay a dividend?

A

There are no upcoming dividends for CRISPR Therapeutics.

Q

When is CRISPR Therapeutics (NASDAQ:CRSP) reporting earnings?

A

CRISPR Therapeutics does not have any upcoming earnings scheduled.

Q

Is CRISPR Therapeutics (CRSP) going to split?

A

There is no upcoming split for CRISPR Therapeutics.

Q

What sector and industry does CRISPR Therapeutics (CRSP) operate in?

A

CRISPR Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.